Categories: CancerNews

Canopy and Willamette Valley Cancer Institute and Research Center Announce Partnership to Improve Care Between Visits

NEW YORK, Nov. 3, 2025 /PRNewswire/ — Canopy, the leader in Enterprise AI for oncology, today announced a partnership with Willamette Valley Cancer Institute and Research Center (WVCI), a leader in advanced cancer treatments for over 25 years, to improve care between visits for both patients and staff.

“We continuously evaluate technology solutions to help us provide better care for our patients while lowering the administrative burden for our staff,” said Casey Chiasson, MBA, Executive Director of Willamette Valley Cancer Institute and Research Center. “With Canopy, we’re leveraging best-in-class AI across patient services to achieve this, particularly through remote therapeutic monitoring.”

Canopy helps practices manage the growing complexity of cancer care by providing a single Enterprise AI platform across patient services: triage, call center, referrals, and pharmacy. By embedding AI and automation into existing workflows, Canopy enables faster issue resolution, reduces manual work, and helps practices capture reimbursement to sustain between-visit care through Principal & Chronic Care Management (PCM/CCM), Remote Therapeutic Monitoring (RTM), and more.

“WVCI has built a strong reputation as a leader in research and innovation,” said Lavi Kwiatkowsky, Founder and CEO of Canopy. “We’re proud to advance their mission through technology that enhances efficiency, reduces administrative burden, and delivers innovative solutions such as remote therapeutic monitoring.”

Presentations highlighting the potential impact of Canopy’s platform on oncology patient experience in real-world settings have demonstrated:

  • 37.5% reduction in treatment discontinuation at three months1
  • 22% – 45% improvement in treatment persistence at three months2
  • 22% reduction in ER visits and hospitalizations per 100 patient months3
  • 88% sustained patient engagement at six months4
  • Improved early detection of toxicities with bispecific antibody therapies5

Care teams using Canopy have also seen:

  • 15-minute average resolution time for patient symptom reports6
  • 93% faster resolution of all patient requests compared to prior workflows6

Canopy is contracted with 10% of oncology providers in the U.S. and rapidly growing.

About Canopy

Canopy is Enterprise AI for Oncology, providing practices with a unified platform for all the care that happens between visits and across patient services. Supporting a growing network of more than 2,000 oncology providers nationwide, Canopy enables practices to identify and prioritize patients who need help, resolve their issues using AI-native tools, and generate new reimbursement streams. For more information, visit www.canopycare.us.

About
Willamette Valley Cancer Institute and Research Center

The Willamette Valley Cancer Institute and Research Center has been a leader in advanced cancer treatments for over 25 years, serving the Willamette Valley and surrounding regions including Albany, Corvallis, Eugene, Florence, Lincoln City, Newport, and Springfield, Oregon. WVCI is committed to offering innovative and integrated care, backed by cutting-edge technology and extensive clinical research. Learn more at https://www.oregoncancer.com/.

Media Contact:

Kaitlin Hemric
Canopy
704-838-6168
kaitlin@canopycare.us

1Essell, J. H., Derman, B. A., Kolodziej, M. A., Kwiatkowsky, L., Calkins, G., Parrinello, C. M., & Ascha, M. S. (2024, December 8). Symptoms detection among patients with lymphoid malignancies (LM) using electronic patient-reported outcomes (ePROs) in community hematology-oncology clinics. American Society of Hematology Annual Meeting

2Parrinello, C., Calkins, G., Kwiatkowsky, L., Schaefer, E. S., Beck, J. T., Ellis, A. R., Blau, S., Telivala, B. P., & Kolodziej, M. A. (2022). Time on treatment is prolonged in patients utilizing an ePRO based digital symptom monitoring platform in the community setting. Journal of Clinical Oncology, 40(16_suppl), 1528. DOI: 10.1200/JCO.2022.40.16_suppl.1528

3Kolodziej, M. A., Kwiatkowsky, L., Parrinello, C., Thurow, T., Schaefer, E. S., Beck, J. T., Cherny, N., & Blau, S. (2022). ePRO-based digital symptom monitoring in a community oncology practice to reduce emergency room and inpatient utilization. Journal of Clinical Oncology, 40(16_suppl), 1508

4Cherny, N. I., Parrinello, C. M., Kwiatkowsky, L., Hunnicutt, J., Beck, T., Schaefer, E., Thurow, T., & Kolodziej, M. (2022). Feasibility of Large-Scale Implementation of an Electronic Patient- Reported Outcome Remote Monitoring System for Patients on Active Treatment at a Community Cancer Center. JCO Oncology Practice, 18(12), e1918-e1926. DOI: 10.1200/OP.22.00180

5Derman, B. A., Essell, J. H., Kolodziej, M. A., Kwiatkowsky, L., Calkins, G., Parrinello, C. M., & Ascha, M. S. (2024, December 9). Electronic patient-reported outcome (ePRO) symptom monitoring for relapsed/refractory multiple myeloma in community settings, focusing on bispecific antibody therapy. American Society of Hematology Annual Meeting

6Canopy internal analysis of partnership data

View original content:https://www.prnewswire.com/news-releases/canopy-and-willamette-valley-cancer-institute-and-research-center-announce-partnership-to-improve-care-between-visits-302602656.html

SOURCE Canopy

Staff

Recent Posts

CBIH Welcomes Federal Momentum Toward Cannabis Rescheduling as 2026 Opens a New Window to Accelerate Medical Innovation and Growth, with CBIH Positioned to Capitalize on Emerging Opportunities

Houston, Texas--(Newsfile Corp. - December 22, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) (CBIH) announces…

21 minutes ago

XRP Healthcare® Secures Global Trademark Protection at the Intersection of Healthcare Services and XRP-Powered Payments

Multi-jurisdiction trademark coverage reinforces XRP Healthcare's position across digital health, pharmacy networks, and XRP-based payment…

1 hour ago

Black Book Poll: “Governed AI” Emerges as the Deciding Factor in 2026 NHS Procurement

Respondents report approvals and evaluation readiness are now the bottlenecks driving demand for reusable safety…

1 hour ago

Hemogenyx Pharmaceuticals PLC Announces Update on Admission of Shares

LONDON, UK / ACCESS Newswire / December 22, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the…

1 hour ago

What Is the Best GLP-1 Supplement for Weight Loss? Industry Analysis Reveals Probiotic Akkermansia Formulas as Affordable Ozempic Alternatives

Health Journey Addresses 'Best GLP-1 Supplement' Question with Akkermansia-Based Formula Analysis as Six-Month Costs Compare…

22 hours ago